Impact of total cumulative glucocorticoid dose on bone mineral density in patients with 21-hydroxylase deficiency
The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: It remains controversial whether long-term glucocorticoids are charged of bone demineralization in patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. The aim of this study was to know whether cumulative glucocorticoid dose from the diagnosis in childhood to adulthood in patients with CAH had a negative impact on bone mineral density (BMD). DESIGN: This was a retrospective study. METHODS: Thirty-eight adult patients with classical and non-classical CAH were included. BMD was measured in the lumbar spine and femoral neck. Total cumulative glucocorticoid (TCG) and total average glucocorticoid (TAG) doses were calculated from pediatric and adult files. RESULTS: We showed a difference between final and target heights (-0.82+/-0.92 s.d. for women and -1.31+/-0.84 s.d. for men; P<0.001). Seventeen patients (44.7%) had bone demineralization (35.7% of women and 70% of men). The 28 women had higher BMD than the 10 men for lumbar (-0.26+/-1.20 vs -1.25+/-1.33 s.d.; P=0.02) and femoral T-scores (0.21+/-1.30 s.d. versus -1.08+/-1.10 s.d.; P=0.007). In the salt-wasting group, women were almost significantly endowed with a better BMD than men (P=0.053). We found negative effects of TCG, TAG on lumbar (P<0.001, P=0.002) and femoral T-scores (P=0.006, P<0.001), predominantly during puberty. BMI was protective on BMD (P=0.006). CONCLUSION: The TCG is an important factor especially during puberty for a bone demineralization in patients with 21-hydroxylase deficiency. The glucocorticoid treatment should be adapted particularly at this life period and preventive measures should be discussed in order to limit this effect.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Using the WHO definition of reduced BMD 16, the prevalence of reduced BMD in previous CAH studies ranges between 45–60% 3, 4, 17 as compared to 52% in our cohort.”
From Cortical bone mineral density in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency (2015) · cites this paper as [17]
In the citing paper
“Chakhtoura et al. (266) showed a negative correlation between the cumulative lifetime GC dose and BMD.”
From Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline (2018) · cites this paper as [266]
Citations
Cites
Variations in pattern of pubertal changes in girls
Marshall, W. A., & Tanner, J. M. (1969) · Archives of Disease in Childhood · doi:10.1136/adc.44.235.291 · Cited by 5,963 · cited 1×
“The onset of puberty was noted (B2 in girls (16) and testes size greater than 20 x 30 mm in boys (17)) as well as height and bone age at the beginning of puberty.”
BackgroundVariations in the pattern of pubertal changes in boys
Marshall, W. A., & Tanner, J. M. (1970) · Archives of Disease in Childhood · doi:10.1136/adc.45.239.13 · Cited by 5,147 · cited 1×
“The onset of puberty was noted (B2 in girls (16) and testes size greater than 20 x 30 mm in boys (17)) as well as height and bone age at the beginning of puberty.”
BackgroundCongenital adrenal hyperplasia due to 21-hydroxylase deficiency*
White, P. C., & Speiser, P. W. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.3.0398 · Cited by 1,432
Morishima, A., Grumbach, M. M., Simpson, E. R., Fisher, C., & Qin, K. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.12.8530621 · Cited by 1,416 · cited 1×
“Authors of published papers explained that estrogens have more protective action for bone mineralization than androgen (36, 41), which could contribute to this result, all the more since the majority of women took exogenous estrogens.”
BackgroundThe epidemiology of corticosteroid-induced osteoporosis: a meta-analysis
Staa, T. P. V., Staa, T. P. V., Staa, T. P. V., Leufkens, H. G. M., & Cooper, C. (2002) · Osteoporosis International · doi:10.1007/s001980200108 · Cited by 1,294 · cited 2×
“work on 81 patients in 2 randomized, double-masked, placebo-controlled trials (23), where they related the TCG to the bone loss.”
BackgroundBuckley, T. M., & Schatzberg, A. F. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1056 · Cited by 964 · cited 1×
“Indeed, it reduces basal ACTH and 17-OHP by inhibiting hypothalamic–adrenal–pituitary axis ( 49 ).”
BackgroundCongenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency
White, P. C. (2000) · Endocrine Reviews · doi:10.1210/er.21.3.245 · Cited by 877
Clinical Use of Bone Densitometry: Scientific Review
Cummings, S. R., Bates, D., & Black, D. M. (2002) · JAMA · doi:10.1001/jama.288.15.1889 · Cited by 817
Prader, A., Largo, R. H., Molinari, L., & Issler, C. (1989) · PubMed · Cited by 814
Standards for Children's Height at Ages 2-9 Years Allowing for Height of Parents
Tanner, J. M., Goldstein, H., & Whitehouse, R. H. (1970) · Archives of Disease in Childhood · doi:10.1136/adc.45.244.755 · Cited by 812
Steroid-Induced Fractures and Bone Loss in Patients with Asthma
Adinoff, A. D., & Hollister, J. R. (1983) · New England Journal of Medicine · doi:10.1056/nejm198308043090502 · Cited by 674 · cited 1×
“It is recognized that men and premenopausal women may suffer from glucocorticoid-induced osteoporosis (45, 46), and postmenopausal women also have a high risk of fracture during corticosteroid treatment (47).”
BackgroundRecommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update
American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200107)44:7<1496::aid-art271>3.0.co;2-5 · Cited by 647
Van Staa, T. P., Laan, R. F., Barton, I. P., Cohen, S., Reid, D. M., & Cooper, C. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11283 · Cited by 559 · cited 1×
“It is recognized that men and premenopausal women may suffer from glucocorticoid-induced osteoporosis (45, 46), and postmenopausal women also have a high risk of fracture during corticosteroid treatment (47).”
BackgroundConvergence between bone and energy homeostases: Leptin regulation of bone mass
Karsenty, G. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.10.008 · Cited by 418 · cited 1×
“adipocyte secretion of leptin which regulates bone mass through a hypothalamic relay acting on osteoblasts (44).”
BackgroundIncreases in Bone Density During Treatment of Men with Idiopathic Hypogonadotropic Hypogonadism*
FINKELSTEIN, J. S., KLIBANSKI, A., NEER, R. M., DOPPELT, S. H., ROSENTHAL, D. I., SEGRE, G. V., & CROWLEY, W. F. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-69-4-776 · Cited by 356
Raisz, L. G., & Kream, B. E. (1983) · New England Journal of Medicine · doi:10.1056/nejm198307073090107 · Cited by 341 · cited 1×
“What is more, chronic glucocorticoid therapy is known to generate bone loss in many ways: a direct suppression of osteoblastic activity (2) and an inhibition of digestive calcium absorption with secondary hyperparathyroidism and increased bone resorption by osteoclasts (3).”
BackgroundHAHN, T. J., HALSTEAD, L. R., & BARAN, D. T. (1981) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-52-1-111 · Cited by 308
Stikkelbroeck, N. M. M. L., Otten, B. J., Pasic, A., Jager, G. J., Sweep, C. G. J. F., Noordam, K., & Hermus, A. R. M. M. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.12.8090 · Cited by 305 · cited 1×
“In addition, it appears that adult males with CAH face a dual problem: 1) adrenal steroid overproduction, especially androgen and progesterone which are less protective on BMD than testosterone, might interfere with FSH and LH production, resulting in gonadotropin deficiency and consequent small testicular size and lo…”
BackgroundArlot, M. E., Sornay-Rendu, E., Garnero, P., Vey-Marty, B., & Delmas, P. D. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.4.683 · Cited by 299 · cited 11×
“Since BMD was characterized by two variables (lumbar and femoral T-scores), significance level was Bonferroni corrected: a P!”
MethodInfluentialKerrigan, J. R., Veldhuis, J. D., Leyo, S. A., Iranmanesh, A., & Rogol, A. D. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.76.6.8501158 · Cited by 228 · cited 1×
“Many studies have pointed out that normal endogenous cortisol production is around 7 mg/m2/d in healthy people (38, 39), whereas clinicians advocate 10 to 15 mg/m2/d of exogenous therapy (40), which can bring on corticosteroid side effects in bone and result in subnormal androgen levels.”
BackgroundLong Term Outcome in Adult Males with Classic Congenital Adrenal Hyperplasia1
Cabrera, M. S., Vogiatzi, M. G., & New, M. I. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.7.7668 · Cited by 204
Cortisol production rate in childhood and adolescence
Linder, B. L., Esteban, N. V., Yergey, A. L., Winterer, J. C., Loriaux, D. L., & Cassorla, F. (1990) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)80128-3 · Cited by 202 · cited 1×
“Many studies have pointed out that normal endogenous cortisol production is around 7 mg/m2/d in healthy people (38, 39), whereas clinicians advocate 10 to 15 mg/m2/d of exogenous therapy (40), which can bring on corticosteroid side effects in bone and result in subnormal androgen levels.”
BackgroundEugster, E. A., DiMeglio, L. A., Wright, J. C., Freidenberg, G. R., Seshadri, R., & Pescovitz, O. H. (2001) · The Journal of Pediatrics · doi:10.1067/mpd.2001.110527 · Cited by 197 · cited 1×
“We noted low final height compared to target height, consistent with former publications (25-28), while onset-pubertal height was normal.”
ResultBonfig, W., Bechtold, S., Schmidt, H., Knorr, D., & Schwarz, H. P. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2109 · Cited by 167 · cited 1×
“We noted low final height compared to target height, consistent with former publications (25-28), while onset-pubertal height was normal.”
ResultGlucocorticoid-induced osteoporosis
Saag, K. G. (2003) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(02)00064-6 · Cited by 164
Fractures and bone mineral density in adult women with 21-hydroxylase deficiency
Falhammar, H., Filipsson, H., Holmdahl, G., Janson, P.-O., Nordenskjöld, A., Hagenfeldt, K., & Thorén, M. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0744 · Cited by 151 · cited 2×
“(15); therefore, preventive methods might be introduced, including physical activity and diet-recommendations and vitamin D supplementation if necessary (48).”
BackgroundFractures in rheumatoid arthritis: an evaluation of associated risk factors.
Michel, B. A., Bloch, D. A., Wolfe, F., & Fries, J. F. (1993) · PubMed · Cited by 146
6 Drug-induced disorders of vitamin D and mineral metabolism
Hahn, T. J. (1980) · Clinics in Endocrinology and Metabolism · doi:10.1016/s0300-595x(80)80023-5 · Cited by 144 · cited 1×
“Glucocorticoids also seem to regulate renal calcium excretion and parathormone secretion ( 4 ).”
BackgroundGirgis, R., & Winter, J. S. D. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.12.4320 · Cited by 139 · cited 1×
“Conversely, overtreated children suffer from growth retardation (32, 33).”
BackgroundStikkelbroeck, N. M. M. L., Oyen, W. J. G., van der Wilt, G.-J., Hermus, A. R. M. M., & Otten, B. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021074 · Cited by 138
Bone mineral density and body composition in congenital adrenal hyperplasia.
Cameron, F. J., Kaymakci, B., Byrt, E. A., Ebeling, P. R., Warne, G. L., & Wark, J. D. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.7.7608286 · Cited by 114 · cited 1×
“Some studies reported no significant differences in bone mineral density (BMD) between patients and controls (5-9), whereas others found impaired BMD (10-15).”
BackgroundHagenfeldt, K., Martin Ritzen, E., Ringertz, H., Helleday, J., & Carlstrom, K. (2000) · European Journal of Endocrinology · doi:10.1530/eje.0.1430667 · Cited by 110 · cited 1×
“Some studies reported no significant differences in bone mineral density (BMD) between patients and controls (5-9), whereas others found impaired BMD (10-15).”
BackgroundLong-Term Outcome of Patients with Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency
Bachelot, A., Plu-Bureau, G., Thibaud, E., Laborde, K., Pinto, G., Samara, D., Nihoul-Fékété, C., Kuttenn, F., Polak, M., & Touraine, P. (2007) · Hormone Research in Paediatrics · doi:10.1159/000098017 · Cited by 106
Self-citationLong Term Outcome in Adult Males with Classic Congenital Adrenal Hyperplasia
Cabrera, M. S. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.7.3070 · Cited by 105
King, J. A., Wisniewski, A. B., Bankowski, B. J., Carson, K. A., Zacur, H. A., & Migeon, C. J. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0745 · Cited by 104
Longitudinal analysis of growth and puberty in 21-hydroxylase deficiency patients
Van der Kamp, H. J. (2002) · Archives of Disease in Childhood · doi:10.1136/adc.87.2.139 · Cited by 104 · cited 1×
“Height gain was also reported as poor during pubertal years in studies conducted by Stikkelbroeck et al. (29) and van der Kamp et al. ( 30 ).”
ResultBalsamo, A., Cicognani, A., Baldazzi, L., Barbaro, M., Baronio, F., Gennari, M., Bal, M., Cassio, A., Kontaxaki, K., & Cacciari, E. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030123 · Cited by 102 · cited 1×
“We noted low final height compared to target height, consistent with former publications (25-28), while onset-pubertal height was normal.”
ResultPinto, G., Tardy, V., Trivin, C., Thalassinos, C., Lortat-Jacob, S., Nihoul-Fékété, C., Morel, Y., & Brauner, R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021433 · Cited by 101 · cited 1×
“We noted low final height compared to target height, consistent with former publications (25-28), while onset-pubertal height was normal.”
ResultBone density in young patients with congenital adrenal hyperplasia
Mora, S., Saggion, F., Russo, G., Weber, G., Bellini, A., Prinster, C., & Chiumello, G. (1996) · Bone · doi:10.1016/8756-3282(96)00003-8 · Cited by 95 · cited 1×
“Some studies reported no significant differences in bone mineral density (BMD) between patients and controls (5-9), whereas others found impaired BMD (10-15).”
BackgroundJääskeläinen, J., & Voutilainen, R. (1996) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1996.8620871.x · Cited by 92 · cited 3×
“(10) chose a current and mean long-term glucocorticoid dose, Hagenfeldt et al.”
BackgroundGussinyé, M., Carrascosa, A., Potau, N., Enrubia, M., Vicens-Calvet, E., Ibáñez, L., & Yeste, D. (1997) · PEDIATRICS · doi:10.1542/peds.100.4.671 · Cited by 90 · cited 1×
“work which BMD values of adolescent and young adult CAH patients were significantly lower than those of the age- and sex-matched controls, whereas it did not differ between prepubertal patients and controls (34).”
ResultSciannamblo, M., Russo, G., Cuccato, D., Chiumello, G., & Mora, S. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2823 · Cited by 82 · cited 2×
“(13), the median of the last seven years of treatment, and Stikkelbroeck et al.”
BackgroundBone turnover and bone mineral density in patients with congenital adrenal hyperplasia
Guo, C., Weetman, A. P., & Eastell, R. (1996) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1996.00851.x · Cited by 79
Stikkelbroeck, N. M. M. L., van’t Hof-Grootenboer, B. A. E., Hermus, A. R. M. M., Otten, B. J., & van’t Hof, M. A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-030011 · Cited by 73 · cited 1×
“Height gain was also reported as poor during pubertal years in studies conducted by Stikkelbroeck et al. ( 29 ) and van der Kamp et al. (30).”
ResultRandomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia
Silva, I. N., Kater, C. E., Cunha, C. D. F., & Viana, M. B. (1997) · Archives of Disease in Childhood · doi:10.1136/adc.77.3.214 · Cited by 71 · cited 1×
“Conversely, overtreated children suffer from growth retardation (32, 33).”
BackgroundChristiansen, P., Mølgaard, C., & Müller, J. (2004) · Hormone Research in Paediatrics · doi:10.1159/000075588 · Cited by 61
Arisaka, O., Hoshi, M., Kanazawa, S., Numata, M., Nakajima, D., Kanno, S., Negishi, M., Nishikura, K., Nitta, A., Imataka, M., et al. (2001) · Metabolism · doi:10.1053/meta.2001.21678 · Cited by 50 · cited 2×
“Secondly, glucocorticoids may lead to osteoporosis (35), while androgens are known to increase bone formation markers (36, 37).”
BackgroundMenarche and Subsequent Ovarian Function in Girls with Congenital Adrenal Hyperplasia
Hughes, I. A., & Read, G. F. (1982) · Hormone Research · doi:10.1159/000179489 · Cited by 43 · cited 1×
“mean age of menarche around 13.6G1.6 years, which had also been reported by Hughes et al. ( 24 ) and Bonfig et al. (25).”
Background
Research works printed but not linked: 4
- 2006, Journal of Clinical Endocrinology & Metabolism, 3, 865
- 1989, Helvetica paediatrica acta, 52, 1
- 1995, Journal of Clinical Endocrinology & Metabolism, 80, 2238
- Michel, 1993, The Journal of Rheumatology, 20, 1666
Cited by
Speiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468
“(234) showed a negative correlation between the accumulated lifetime dose of GC and BMD.”
Speiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234
Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients
Arlt, W., Willis, D. S., Wild, S. H., Krone, N., Doherty, E. J., Hahner, S., Han, T. S., Carroll, P. V., Conway, G. S., Rees, D. A., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0917 · Cited by 506
PW, S., W, A., RJ, A., LS, B., GS, C., DP, M., HFL, M.-B., WL, M., MH, M., SE, O., et al. (2019) · Yearbook of Paediatric Endocrinology · doi:10.1530/ey.16.8.5 · Cited by 300
TASK channel deletion in mice causes primary hyperaldosteronism
Davies, L. A., Hu, C., Guagliardo, N. A., Sen, N., Chen, X., Talley, E. M., Carey, R. M., Bayliss, D. A., & Barrett, P. Q. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712000105 · Cited by 198
Metadata
- Authors
- Chakhtoura, Z., Bachelot, A., Samara-Boustani, D., Ruiz, J.-C., Donadille, B., Dulon, J., Christin-Maître, S., Bouvattier, C., Raux-Demay, M.-C., Bouchard, P., Carel, J.-C., Leger, J., Kuttenn, F., Polak, M., & Touraine, P.
- Affiliations
- Assistance Publique – Hôpitaux de Paris (FR)
- ORCID
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-06
- Volume
- 158
- Issue
- 6
- Pages
- 879-887
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2126029954
- Cited by
- 90
- References
- 48
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 3 · 2023: 4 · 2022: 7 · 2021: 6 · 2020: 5 · 2019: 4 · 2018: 5 · 2017: 2 · 2016: 5 · 2015: 5 · 2014: 7 · 2013: 4 · 2012: 4
- FWCI
- 3.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- 10th European Congress of Endocrinology
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Keywords
- 21-hydroxylase deficiency, congenital adrenal hyperplasia, glucocorticoid therapy, cumulative glucocorticoid dose, bone mineral density, bone demineralization, puberty, sex differences, body mass index, salt-wasting CAH, lumbar spine, femoral neck
- MeSH terms
- Adolescent, Adrenal Hyperplasia, Congenital, Adult, Body Height, Female, Glucocorticoids, Humans, Male, Puberty, Retrospective Studies, Steroid 21-Hydroxylase, Absorptiometry, Photon, Bone Density
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.